Drug intelligence / Profile preview

HRS8807 + SHR6390

Development stage: Unknown
Lead developer: Shanghai Hengrui Pharmaceutical Co., Ltd.
Modality: Small Molecules
Administration: Oral

Overview

**HRS8807 + SHR6390** is a combination of two small molecule drugs evaluated for the treatment of ER-positive, HER2-negative metastatic or locally advanced breast cancer. HRS8807 acts as an inhibitor of Ca2+-ATPases, particularly targeting sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), while SHR6390 (dalpiciclib) is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). This drug combination is in phase 1 clinical studies assessing safety, tolerability, and pharmacokinetics. HRS8807 is developed by Shanghai Hengrui Pharmaceutical and Jiangsu Hengrui Pharmaceuticals[1][2][5].

Targets

ATP2A (Sarcoplasmic reticulum Ca2+-ATPase)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)

Beyond the preview

Go deeper on HRS8807 + SHR6390.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS8807 + SHR6390.

Explore the full profile